Daniella Muallem Schwartz

Daniella Muallem Schwartz

Auto-generated profile, based on publicly available information

Daniella Muallem Schwartz

University of Pittsburgh, Departments of Medicine and Immunology, Division of Rheumatology, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2015 in Annual Review of Medicine
Verified
Journal Article
Closed access
JOJohn J. O'Shea
John J. O'Shea
DSDaniella M. Schwartz
Daniella M. Schwartz
AVAlejandro V. Villarino
Alejandro V. Villarino
MGMassimo Gadina
Massimo Gadina
IMIain B. McInnes
Iain B. McInnes
ALArian Laurence
Arian Laurence
The Janus kinase (JAK)–signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related molecules. This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression. It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation. Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, especially cancer and immune-related conditions. The clinical relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.

3 March 2017 in Drugs
Verified
Journal Article
Closed access
PDF file
SBShubhasree Banerjee
Shubhasree Banerjee
ABAnn Biehl
Ann Biehl
MGMassimo Gadina
Massimo Gadina
SHSarfaraz Hasni
Sarfaraz Hasni
DSDaniella M. Schwartz
Daniella M. Schwartz

6 November 2017 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
DSDaniella M. Schwartz
Daniella M. Schwartz
YKYuka Kanno
Yuka Kanno
AVAlejandro Villarino
Alejandro Villarino
MWMichael Ward
Michael Ward
MGMassimo Gadina
Massimo Gadina
JOJohn J. O'Shea
John J. O'Shea

7 December 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
QZQing Zhou
Qing Zhou
HWHongying Wang
Hongying Wang
DSDaniella M Schwartz
Daniella M Schwartz
MSMonique Stoffels
Monique Stoffels
YPYong Hwan Park
Yong Hwan Park
IAIvona Aksentijevich
Ivona Aksentijevich
Ivona Aksentijevich and colleagues identify heterozygous loss-of-function mutations in TNFAIP3 (encoding A20) in six unrelated families with early-onset systemic inflammation. Affected individuals exhibit increased expression of NF-κB–mediated proinflammatory cytokines, consistent with the established role of A20 as a potent inhibitor of the NF-κB signaling pathway. Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity1. Herein we describe a new disease caused by high-penetrance heterozygous germline mutations in TNFAIP3, which encodes the NF-κB regulatory protein A20, in six unrelated families with early-onset systemic inflammation. The disorder resembles Behçet's disease, which is typically considered a polygenic disorder with onset in early adulthood2. A20 is a potent inhibitor of the NF-κB signaling pathway3. Mutant, truncated A20 proteins are likely to act through haploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments. Patient-derived cells show increased degradation of IκBα and nuclear translocation of the NF-κB p65 subunit together with increased expression of NF-κB–mediated proinflammatory cytokines. A20 restricts NF-κB signals via its deubiquitinase activity. In cells expressing mutant A20 protein, there is defective removal of Lys63-linked ubiquitin from TRAF6, NEMO and RIP1 after stimulation with tumor necrosis factor (TNF). NF-κB–dependent proinflammatory cytokines are potential therapeutic targets for the patients with this disease.

3 December 2015 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
DSDaniella M. Schwartz
Daniella M. Schwartz
MBMichael Bonelli
Michael Bonelli
MGMassimo Gadina
Massimo Gadina
JOJohn J. O'SHea
John J. O'SHea

28 December 2017 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
DSDaniella M. Schwartz
Daniella M. Schwartz
YKYuka Kanno
Yuka Kanno
AVAlejandro Villarino
Alejandro Villarino
MWMichael Ward
Michael Ward
MGMassimo Gadina
Massimo Gadina
JOJohn J. O'Shea
John J. O'Shea
Nature Reviews Drug Discovery 16, 843–862 (2017) In the version of this article that was originally published, there was an error in Figure 3 on page 847. In this figure, the structure attributed to the compound BMS-986165 is incorrect and the correct structure for this compound has not yet been disclosed.